Chronic Rhinosinusitis Without Nasal Polyps
Prevalence
12000.0 / 100K
Incidence
1000.0 / 100K/yr
4 drugs in development·4 companies·2 clinical trials
Drug Pipeline by Phase
Approved(1)
| Drug | Company |
|---|---|
| xhance | Paratek Pharmaceuticals, Inc. (PRTK) |
Phase 3(1)
| Drug | Company |
|---|---|
| Mometasone furoate nasal spray | Sanofi (SNY) |
Phase 2(1)
BLA Filed(1)
| Drug | Company |
|---|---|
| xhance | OptiNose, Inc. (OPTN) |
Compare drugs
Frequently asked questions
How many drugs are in development for Chronic Rhinosinusitis Without Nasal Polyps?
BioSniper tracks 4 drugs in development for Chronic Rhinosinusitis Without Nasal Polyps across 4 companies.
How many clinical trials target Chronic Rhinosinusitis Without Nasal Polyps?
There are 2 clinical trials targeting Chronic Rhinosinusitis Without Nasal Polyps tracked by BioSniper.
What is the prevalence of Chronic Rhinosinusitis Without Nasal Polyps?
The estimated prevalence of Chronic Rhinosinusitis Without Nasal Polyps is approximately 12000.0 per 100,000 population.
Deep-dive into Chronic Rhinosinusitis Without Nasal Polyps
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis